Biomedical Frontiers, Inc.

Basic Information

1095 Tenth Avenue, S.E.
Minneapolis, MN, 55413

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. MACROMOLECULAR CONTRAST AGENTS FOR MAGNETIC RESONANCE

    Amount: $675,000.00

    BIOMEDICAL FRONTIERS (BMF) HAS ESTABLISHED THAT THE IRON CHELATOR, DEFEROXAMINE, CAN BE COVALENTLY BOUND TO POLYMERS AND HAS DEMONSTRATED, IN PRECLINICAL STUDIES, THAT THESE CONJUGATES CAN BE USED THE ...

    SBIR Phase II 1994 Department of Health and Human Services
  2. Tumor Growth Inhibition by Iron Deprivation

    Amount: $80,250.00

    This research will determine the potential utility of novel high molecular weight iron chelatorsas anti-cancer agents or adjuncts to other iron-depriving therapeutic strategies in the treatment ofcanc ...

    SBIR Phase I 1994 Department of Health and Human Services
  3. MACROMOLECULAR CONTRAST AGENTS FOR MAGNETIC RESONANCE

    Amount: $50,000.00

    N/A

    SBIR Phase I 1991 Department of Health and Human Services
  4. SYNTHESIS OF HIGH MOLECULAR WEIGHT IRON CHELATORS

    Amount: $249,000.00

    IN CHEMICAL AND BIOLOGICAL SYSTEMS, IRON IS BOTH UBIQUITOUS AND HIGHLY REACTIVE. IN A VARIETY OF CIRCUMSTANCES, THERE IS GREAT NEED FOR NEW APPROACHES TO THE REMOVAL OF IRON OR THE CONTROL OF ITS REAC ...

    SBIR Phase II 1987 Department of Health and Human Services
  5. SYNTHESIS OF HIGH MOLECULAR WEIGHT IRON CHELATORS

    Amount: $44,000.00

    N/A

    SBIR Phase I 1986 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government